Ország: Ausztrália
Nyelv: angol
Forrás: Department of Health (Therapeutic Goods Administration)
bosutinib monohydrate, Quantity: 516.98 mg (Equivalent: bosutinib, Qty 500 mg)
Pfizer Australia Pty Ltd
bosutinib monohydrate
Tablet, film coated
Excipient Ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; poloxamer; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350
Oral
30, 28
(S4) Prescription Only Medicine
BOSULIF (bosutinib monohydrate) is indicated for the treatment of chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid Ieukaemia (CML) in adult patients previously treated with two or more tyrosine kinase inhibitors
Visual Identification: Red, oval biconvex, film coated tablets debossed with "Pfizer" on one side and "500" on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 48 Months; Container Temperature: Store below 30 degrees Celsius
Licence status A
2014-04-29